Changes in bone biochemical markers after high-dose cerivastatin treatment in a woman with osteogenesis imperfecta.
Sugiyama
T
T
Department of Orthopedic Surgery, Yamaguchi University School of Medicine, Ube, Japan.
Kawai
S
S
D000284:Administration, Oral; D000328:Adult; D000469:Alkaline Phosphatase / Q000097:blood; D000596:Amino Acids / Q000652:urine; D015415:Biomarkers / Q000097:blood / Q000652:urine; D002784:Cholesterol / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D010013:Osteogenesis Imperfecta / Q000097:blood / Q000188:drug therapy* / Q000652:urine; D010865:Pilot Projects; D011446:Prospective Studies; D011725:Pyridines / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors
D000596:Amino Acids; D015415:Biomarkers; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011725:Pyridines; C036020:deoxypyridinoline; D002784:Cholesterol; C086276:cerivastatin; D000469:Alkaline Phosphatase